Xenon ( DrugBank: Xenon )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
22	もやもや病	1
85	特発性間質性肺炎	3
299	嚢胞性線維症	6

22. もやもや病

臨床試験数 : 17 / 薬物数 : 22 - (DrugBank : 17) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01419275 (ClinicalTrials.gov)	April 2009	16/8/2011	Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients	Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients	Cerebrovascular Accident;Moyamoya Disease	Drug: Xenon contrast agent;Device: Magnetic Resonance Imaging	Stanford University	NULL	Completed	N/A	N/A	All	126	N/A	United States

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05241275 (ClinicalTrials.gov)	July 19, 2022	3/2/2022	Xenon MRI and Progressive ILD	XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD	Idiopathic Pulmonary Fibrosis;Progressive Pulmonary Fibrosis	Drug: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment	Duke University	Boehringer Ingelheim	Recruiting	18 Years	N/A	All	75	Phase 2	United States
2	NCT04071769 (ClinicalTrials.gov)	August 3, 2020	9/8/2019	Genentech Xenon MRI Idiopathic Pulmonary Fibrosis	Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment	Duke University	NULL	Recruiting	18 Years	N/A	All	20	Phase 2	United States
3	NCT02478268 (ClinicalTrials.gov)	May 2015	16/6/2015	Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis	Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: Hyperpolarized 129-Xenon gas;Device: MRI	Bastiaan Driehuys	University of Wisconsin, Madison;National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	N/A	All	64	Phase 1	United States

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04467957 (ClinicalTrials.gov)	November 15, 2020	19/6/2020	Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis	Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis	Cystic Fibrosis	Drug: Initiation of CFTR Modulator;Drug: Hyperpolarized Xenon 129	Children's Hospital Medical Center, Cincinnati	NULL	Active, not recruiting	6 Years	21 Years	All	26	Phase 4	United States
2	NCT03593434 (ClinicalTrials.gov)	July 30, 2018	28/6/2018	Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI	The Effect of Airway Clearance Therapy on Hyperpolarized 129Xenon MRI Compared With Lung Clearance Index and Spirometry in Cystic Fibrosis	Cystic Fibrosis	Drug: hyperpolarized Xenon gas	Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Completed	6 Years	21 Years	All	20		United States
3	NCT03482960 (ClinicalTrials.gov)	May 29, 2018	23/3/2018	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Cystic Fibrosis	Drug: Hyperpolarized Xenon gas;Drug: PFP	University of North Carolina, Chapel Hill	Cystic Fibrosis Foundation	Completed	18 Years	N/A	All	11	Early Phase 1	United States
4	NCT02848560 (ClinicalTrials.gov)	March 2016	26/7/2016	Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI	Validation of MRI as a Sensitive Tool to Longitudinally Monitor CF Lung Disease Progression and Response to CFTR Modulator Therapy in Young Children With CF	Cystic Fibrosis	Drug: Hyperpolarized Xenon	Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	6 Years	12 Years	All	38		United States
5	NCT02740868 (ClinicalTrials.gov)	August 2015	19/8/2015	Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease	Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease	Cystic Fibrosis;Asthma	Drug: Xenon-129;Device: Magnetic Resonance Imaging;Device: Lung Clearance Index	The Hospital for Sick Children	NULL	Recruiting	8 Years	N/A	All	30	Phase 2	Canada
6	EUCTR2019-003052-36-GB (EUCTR)		28/02/2020	Magnetic Resonance Imaging (MRI) in Bronchiectasis	Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis - MRI in Bronchiectasis	Cystic fibrosis (CF) Non-CF Bronchiectasis MedDRA version: 21.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: hyperpolarized xenon-129 Product Name: hyperpolarized xenon-129	The University of Nottingham	NULL	NA			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

先頭へ